Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
PHOENIX, Oct. 09, 2017 -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the Oppenheimer Specialty Pharma Summit to be held Oct. 11, 2017 at the Sofitel Hotel in New York.
Management will provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference. The presentation slides will be available during the conference and can be accessed by visiting the News & Events page of the Investors section of the company’s website at https://www.insysrx.com/.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray), CII, and SYNDROS® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
CONTACT:
Media Relations
Joe McGrath
Senior Director, Corporate Communications
INSYS Therapeutics
480-500-3101
[email protected]
Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
[email protected]
